› Forums › General Melanoma Community › ASCO 2017: Anti-LAG-3 plus nivo, for melanoma already treated with anti-PD-1/PD-L1
- This topic has 3 replies, 3 voices, and was last updated 8 years, 9 months ago by
Bubbles.
- Post
-
- June 9, 2017 at 3:08 pm
As promised, another post on a "novel therapy". Here patients were post anti-PD-1 or anti-PD-L1 and many were post ipi as well:
For what it's worth. celeste
- Replies
-
-
- June 9, 2017 at 4:40 pm
Hi Celeste, if you remember back to the data on early phase 1 Ipi/ nivo trials and Nivo monotherapy trials, the patients had gone through various treatments before entering the trials. If I remember Dr. Sznol described the patient population as pretty beat up before starting, this new trial sounds very similiar with patients having to have already been through Ipi,Nivo and some targeted therapy as well. I hope the day doesn't come that I have to look for another option, but every small inprovement in % means more melanoma patients surviving and hopefully finding the magic bullet. Thanks for all the ASCO posts!!!Ed
-
- June 10, 2017 at 3:20 pm
You are exactly right, Edster!!! There are a couple of issues. 1. The different responses attained when folks are treatment naive vs those who have already endured a lot. 2. Despite the huge strides that have been made in melanoma treatment…the unacceptable numbers of folks who can STILL get left behind in their search for an effective treatment. (I put some of those thoughts/data together in the preamble to this post: http://chaoticallypreciselifeloveandmelanoma.blogspot.com/2017/06/asco-2017-pembro-plus-entinostat.html
I am very hopeful that you will NOT have to seek another therapy…but for all of us who still need them…or might….you said it perfectly: 'every small improvement in % means more melanoma patients surviving'!!!!
Thanks to all the mice, hopefully those numbers will continue to climb!!! – love you! c
-
- You must be logged in to reply to this topic.